All Stories

  1. Preclinical profile of cabazitaxel

    Article • Drug Design Development and Therapy, October 2014, Taylor & Francis

    PhD Patricia Vrignaud, Dr Sunil Gupta

  2. Efficacy of cabazitaxel in mouse models of pediatric brain tumors

    Article • Neuro-Oncology, August 2014, Oxford University Press (OUP)

    PhD Patricia Vrignaud

  3. Abstract P2-05-08: Combined neoadjuvant iniparib and carboplatin in locally advanced or metastatic canine mammary tumors (MT) to support human clinical studies

    Article • Cancer Research, December 2013, American Association for Cancer Research (AACR)

    PhD Patricia Vrignaud

  4. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel

    Article • Cancer Chemotherapy and Pharmacology, July 2013, Springer Science + Business Media

    PhD Patricia Vrignaud

  5. Abstract 5508: Antitumor activity of cabazitaxel in pediatric patient-derived tumor xenografts (PDX).

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    PhD Patricia Vrignaud

  6. Abstract 5055: Efficacy of cabazitaxel in mouse models of pediatric brain tumors.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    PhD Patricia Vrignaud

  7. Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors

    Article • Clinical Cancer Research, April 2013, American Association for Cancer Research (AACR)

    PhD Patricia Vrignaud

  8. Abstract LB-34: Similar PI3K and RTK-Ras status in patient derived colorectal cancer-xenografts and patients.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    PhD Patricia Vrignaud

  9. Abstract 2785: Development program of patient tumor tissue bank to support the drug and target discovery.:

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    PhD Patricia Vrignaud

  10. P05.08 * SIMILAR PI3K AND RTK-RAS STATUS IN PATIENT DERIVED COLORECTAL CANCER-XENOGRAFTS AND PATIENTS

    Article • Annals of Oncology, March 2013, Oxford University Press (OUP)

    PhD Patricia Vrignaud

  11. Novel Taxanes: Cabazitaxel Case Study

    Article • December 2012, Wiley

    PhD Patricia Vrignaud

  12. Intérêt d’une collaboration entre les tumorothèques et les modèles animaux : taux élevé de prise des xénogreffes issues de carcinomes non à petites cellules humains dans un circuit complexe

    Article • Annales de Pathologie, November 2012, Elsevier

    PhD Patricia Vrignaud

  13. Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer

    Article • Clinical Cancer Research, July 2012, American Association for Cancer Research (AACR)

    PhD Patricia Vrignaud

  14. Abstract 2775: Antitumor activity of cabazitaxel in pediatric tumor xenografts

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    PhD Patricia Vrignaud

  15. Generation of a Conditionally Transformed Murine Embryonic Fibroblast Cell Line Using Doxycycline-Dependent IGF-1R Overexpression

    Article • SLAS DISCOVERY, March 2012, Elsevier

    PhD Patricia Vrignaud

  16. Abstract C162: Influence of tumor genotype on aflibercept (VEGF Trap) antitumor activity in preclinical tumors.

    Article • Molecular Cancer Therapeutics, November 2011, American Association for Cancer Research (AACR)

    PhD Patricia Vrignaud

  17. Abstract 2522: Therapeutic synergism of cabazitaxel in combination with cisplatin in tumor-bearing mice

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    PhD Patricia Vrignaud

  18. Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma

    Article • European Journal of Cancer, December 2010, Elsevier

    PhD Patricia Vrignaud

  19. Abstract 714: Non-invasive monitoring of the antitumor activity of SAR650984 anti-CD38 antibody against disseminated human Daudi lymphoma using 18 F-FDG micro Positron Emission Tomography

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    PhD Patricia Vrignaud

  20. Abstract 4169: CReMEC initiative: Characterization of patient-derived colorectal tumor models and correlation with patient profile

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    PhD Patricia Vrignaud

  21. 525 POSTER Preclinical evaluation of SAR566658 (huDS6-DM4) in mice bearing human tumor xenografts of breast, ovarian, lung, cervical and pancreatic cancer

    Article • European Journal of Cancer Supplements, October 2008, Elsevier

    PhD Patricia Vrignaud

  22. 562 POSTER The anti-insulin-like growth factor I receptor antibody EM164 (murine AVE1642) enhances anti-tumor activity of temozolomide against neuroblastoma cell lines and xenografts

    Article • European Journal of Cancer Supplements, October 2008, Elsevier

    PhD Patricia Vrignaud

  23. Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography

    Article • Investigative Radiology, February 2008, Wolters Kluwer Health

    PhD Patricia Vrignaud

  24. Rythme d’expression de la protéine BCL-2 chez la souris porteuse de l’adénocarcinome mammaire MA13/C

    Article • Pathologie Biologie, June 2003, Elsevier

    PhD Patricia Vrignaud

  25. RPR 130401, a Nonpeptidomimetic Farnesyltransferase Inhibitor with in Vivo Activity

    Article • Annals of the New York Academy of Sciences, December 1999, Wiley

    PhD Patricia Vrignaud

  26. In vivo evaluation of the lrinotecan-oxaliplatin comblnation

    Article • European Journal of Cancer, September 1997, Elsevier

    PhD Patricia Vrignaud

  27. Preclinical Antitumor Activity and Pharmacokinetics of Irinotecan (CPT‐11) in Tumor‐bearing Mice

    Article • Annals of the New York Academy of Sciences, December 1996, Wiley

    PhD Patricia Vrignaud

  28. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice

    Article • Anti-Cancer Drugs, June 1996, Wolters Kluwer Health

    PhD Patricia Vrignaud

  29. Syntheses and Structure−Activity Relationships of the Second-Generation Antitumor Taxoids:  Exceptional Activity against Drug-Resistant Cancer Cells

    Article • Journal of Medicinal Chemistry, January 1996, American Chemical Society (ACS)

    PhD Patricia Vrignaud

  30. Syntheses and Structure—Activity Relationships of New Taxoids

    Article • December 1994, American Chemical Society (ACS)

    PhD Patricia Vrignaud

  31. Synthesis and Structure-Activity Relationships of New Antitumor Taxoids. Effects of Cyclohexyl Substitution at the C-3' and/or C-2 of Taxotere (Docetaxel)

    Article • Journal of Medicinal Chemistry, August 1994, American Chemical Society (ACS)

    PhD Patricia Vrignaud

  32. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice

    Article • Investigational New Drugs, December 1993, Springer Science + Business Media

    PhD Patricia Vrignaud

  33. Assessment of the experimental model of transplanted C6 glioblastoma in wistar rats

    Article • Journal of Neuro-Oncology, September 1989, Springer Science + Business Media

    PhD Patricia Vrignaud, Dr Jacques Robert

  34. Alteration of ganglioside composition and metabolism in doxorubicin-resistant rat tumoral cells

    Article • Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, December 1988, Elsevier

    PhD Patricia Vrignaud, Dr Jacques Robert

  35. Free fatty acid uptake is increased in doxorubicin-resistant glioblastoma cells

    Article • Biochimica et Biophysica Acta (BBA) - Biomembranes, August 1987, Elsevier

    PhD Patricia Vrignaud, Dr Jacques Robert

  36. Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated prefused rat liver

    Article • Cancer Chemotherapy and Pharmacology, May 1987, Springer Science + Business Media

    PhD Patricia Vrignaud, Dr Jacques Robert

  37. Pharmacokinetics of doxorubicin in sarcoma patients

    Article • European Journal of Clinical Pharmacology, January 1987, Springer Science + Business Media

    PhD Patricia Vrignaud, Dr Jacques Robert

  38. Metabolism of doxorubicin and epirubicin in adult human hepatocytes in culture

    Article • Pharmacological Research Communications, April 1986, Elsevier

    PhD Patricia Vrignaud, Dr Jacques Robert

  39. Hepatic metabolism of doxorubicin in mice and rats

    Article • European Journal of Drug Metabolism and Pharmacokinetics, April 1986, Springer Science + Business Media

    PhD Patricia Vrignaud, Dr Jacques Robert

  40. Cellular Pharmacology of Doxorubicin in Sensitive and Resistant Rat Glioblastoma Cells in Culture

    Article • Oncology, January 1986, Karger Publishers

    PhD Patricia Vrignaud, Dr Jacques Robert

  41. Fatty Acid Composition and Metabolism of Tumor Cells Rendered Resistant to the Anticancer Drug Doxorubicin

    Article • January 1986, Springer Science + Business Media

    PhD Patricia Vrignaud

  42. Hepatic metabolism of doxorubicin in mice and rats

    Article • European Journal of Cancer and Clinical Oncology, November 1985, Elsevier

    PhD Patricia Vrignaud

  43. Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients

    Article • European Journal of Cancer and Clinical Oncology, November 1985, Elsevier

    PhD Patricia Vrignaud, Dr Jacques Robert

  44. Cellular Pharmacokinetics of Doxorubicin in Cultured Mouse Sarcoma Cells Originating from Autochthonous Tumors

    Article • Oncology, January 1984, Karger Publishers

    PhD Patricia Vrignaud, Dr Jacques Robert

  45. Early-phase pharmacokinetics of doxorubicin in non-hodgkin lymphoma patients

    Article • Cancer Chemotherapy and Pharmacology, February 1983, Springer Science + Business Media

    PhD Patricia Vrignaud, Dr Jacques Robert

  46. From Random Screening of Chemical Libraries to the Optimization of FPP-Competitive Inhibitors of Farnesyltransferase

    Article • Springer Science + Business Media

    PhD Patricia Vrignaud